tbuckley/cabot-search huggingface dataset:
Initial Results from an International Study in Relapsed/Refractory Aggressive Non-Hodgkin’s Lymphoma To Confirm the Activity, Safety and Criteria for Predicting Response to Lenalidomide Monotherapy.
Authors: Thomas E. Witzig, Craig B. Reeder, Jonathan Polikoff, Naveed M. Chowhan, Isaac Esseessee, Richard Greenberg, Hermant Patel, Davood Vafai, Peter H. Wiernik, Annette Ervin-Haynes, Dennis Pietronigro, Jerome B. Zeldis, Myron Czuczman
Journal: Blood (2007)
A Phase II, Open Label Study of AT-101 in Combination with Rituximab in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia.
Authors: Januario E. Castro, Loria J. Olivier, Aguillon A. Robier, James Danelle, Suarez J. Carlos, Yeh Bi-Ying, Kipps J. Thomas
Journal: Blood (2006)
Lumen-apposing covered self-expandable metal stents for short benign gastrointestinal strictures: a multicenter study
Authors: Dennis Yang, Jose Nieto, Ali Siddiqui, Brian Riff, Christopher DiMaio, Satish Nagula, Amr Ismail, Saowanee Ngamreungphong, Mouen Khashab, Mihir Wagh, Demetrios Tzimas, Jonathan Buscaglia, Daniel Strand, Andrew Wang, Shailendra Chauhan, Christopher Forsmark, Peter Draganov
Journal: Endoscopy (2017)

<b>Background and study aim</b> Use of the fully covered self-expandable metal stent (SEMS) for benign luminal gastrointestinal (GI) stricture (BLGS) has been limited by the migration rate. The role of the lumen-apposing metal stent (LAMS) for BLGS is not well defined. We assessed the safety, feasibility, and efficacy of LAMS for the treatment of BLGS. <b>Patients and methods</b> This was an observational, open-label, retrospective, single-arm, multicenter consecutive case series of patients undergoing LAMS placement for BLGS. Technical success was defined as successful placement of the LAMS. Short- and long-term clinical success rates were defined as symptom improvement/resolution with indwelling stent and after stent removal, respectively. All adverse events and additional interventions were recorded. <b>Results</b> A total of 30 patients (mean age 51.6 years; 63.3 % women) underwent LAMS placement for GI strictures (83.9 % anastomotic). Median stricture diameter and length were 4.5 mm (range 2 – 10 mm) and 8 mm (range 5 – 10 mm), respectively. Technical success was achieved in 29 patients (96.7 %), with an adverse event rate of 13.3 %. The stent migration rate was 8.0 % (2/25) on follow-up endoscopy. Short-term clinical success was achieved in 90.0 % (27/30) at a median of 60 days (interquartile range [IQR] 40 – 90 days). Most patients (19/23; 82.6 %) experienced sustained symptom improvement/resolution without the need for additional interventions at a median follow-up of 100 days (IQR 60 – 139 days) after LAMS removal. <b>Conclusion</b> This multicenter study demonstrated that LAMS placement represents a safe, feasible, and effective therapeutic option for patients with BLGS and is associated with a low stent migration rate. Our initial findings suggest that future prospective comparative studies are needed on the use of LAMS, endoscopic dilation, and conventional SEMS.
A View from the Front Line — Physicians’ Perspectives on ACA Repeal
Authors: Craig Evan Pollack, Katrina Armstrong, David Grande
Journal: New England Journal of Medicine (2017)

Although only 15% of primary care physicians surveyed want the Affordable Care Act repealed, 74% favor making changes to the law. They tend to favor increasing choice for consumers and to oppose shifting more costs to consumers through high-deductible health plans.
Inhibition of the TGF-β Receptor I Can Stimulate Hematopoiesis in Primary Myelodysplastic Syndrome Progenitors as Well as in TGF-β Driven Transgenic Mouse Model of Bone Marrow Failure.
Authors: L. Zhou, A. Nguyen, P. Pahanish, J. Hayman, K. Gundabolu, A. Chubak, S. Parmar, D. Garry, A. Wickrema, T. Navas, L. Higgins, E. Friedman, A. List, M. Bitzer, A. Verma
Journal: Blood (2007)
<i>Notes from the Field:</i> Multistate Outbreak of <i>Escherichia coli</i> O157:H7 Infections Linked to Dough Mix — United States, 2016
Authors: Laura Gieraltowski, Colin Schwensohn, Stephanie Meyer, Dana Eikmeier, Carlota Medus, Alida Sorenson, Matthew Forstner, Asma Madad, Joseph Blankenship, Peter Feng, Ian Williams
Journal: MMWR Morbidity and Mortality Weekly Report (2017)
Population-based analysis of cancer control of partial nephrectomy for high-risk localized renal cell carcinoma.
Authors: Rebecca Leigh O'Malley, Matthew H. Hayn, Greg Wilding, Thomas Schwaab
Journal: Journal of Clinical Oncology (2012)

385 Background: Partial nephrectomy (PN) has reported equivalent oncologic outcomes with superior renal function outcomes when compared to radical nephrectomy (RN) for treatment of localized renal cell carcinoma (RCC). Whether PN provides adequate cancer control in high risk disease is unclear. To clarify, survival outcomes were compared between those who underwent RN and PN for high risk RCC. Methods: Using the Surveillance, Epidemiology, and End Results database patients with RCC who underwent PN or RN for a localized tumor ≤ 7cm were identified. Cancer-specific (CSS) and overall survival (OS) were compared between those with high risk disease (defined as poorly or undifferentiated grade and/or pathologic stage T3) who underwent PN or RN. Results: Of 51,183 patients with localized RCC ≤ 7cm, 24.9% had high risk disease, 85.2% and 14.8% of which underwent RN and PN, respectively. Five-year CSS was superior in the PN group vs. the RN group (93.3% vs. 86.0%, p&lt;0.001). On multivariable analysis undergoing RN was no longer predictive of CSS (HR 1.23, p=0.08). Similarly, 5-year OS was superior in the PN versus RN group (79.5% vs. 70.1%, p&lt;0.001). RN remained independently associated with poor OS on multivariable analysis (HR 1.16, p=0.031). Propensity analysis accounting for factors affecting selection for type of nephrectomy produced similar results. RN did not influence CSS but portended a 20% increased risk of death from all causes (p=0.008). Conclusions: In patients with high risk RCC, partial nephrectomy is associated with improved OS and does not compromise cancer control as compared to radical nephrectomy.
Inability to Express HOXA Cluster and BCL11A Genes Compromises Self-Renewal and Multipotency of hESC-Derived Hematopoietic Cells
Authors: Diana R Dou, Arazin Minasian, Maria I Sierra, Pamela Saarikoski, Jian Xu, Stuart H. Orkin, Sacha L. Prashad, Mattias Magnusson, Jerome A. Zack, Gay M. Crooks, Zoran Galic, Hanna K. A. Mikkola
Journal: Blood (2012)
An artificial intelligence platform for the multihospital collaborative management of congenital cataracts
Authors: Erping Long, Haotian Lin, Zhenzhen Liu, Xiaohang Wu, Liming Wang, Jiewei Jiang, Yingying An, Zhuoling Lin, Xiaoyan Li, Jingjing Chen, Jing Li, Qianzhong Cao, Dongni Wang, Xiyang Liu, Weirong Chen, Yizhi Liu
Journal: Nature Biomedical Engineering (2017)
Efficacy of Recombinant Activated Factor VII (rFVIIa) vs. Activated Prothrombin Complex Concentrate (APCC) in Patients with Hemophilia with Inhibitors: A Bayesian Meta-Analysis.
Authors: Maarten Jacob Treur, Fay McCracken, Bart Heeg, Ashish V. Joshi, Stephanie Thurston, Bram Verheggen, Botteman Marc, Frank de Charro, Ben van Hout
Journal: Blood (2007)
Impact of Persistent Left Ventricular Regional Wall Motion Abnormalities in Childhood Cancer Survivors after Anthracycline Therapy: Assessment of Global Left Ventricular Myocardial Performance By 3D Speckle-Tracking Echocardiography
Authors: Hirotsugu Okuma, Hiroshi Yagasaki, Katsuyoshi Shimozawa, Hideo Mugishima, Nobutaka Noto
Journal: Blood (2014)
Differences in regional air trapping in current smokers with normal spirometry
Authors: Reza Karimi, Göran Tornling, Helena Forsslund, Mikael Mikko, Åsa M. Wheelock, Sven Nyrén, C. Magnus Sköld
Journal: European Respiratory Journal (2017)

We investigated regional air trapping on computed tomography in current smokers with normal spirometry. It was hypothesised that presence of regional air trapping may indicate a specific manifestation of smoking-related changes. 40 current smokers, 40 patients with chronic obstructive pulmonary disease (COPD), and 40 healthy never- smokers underwent computed tomography scans. Regional air trapping was assessed on end-expiratory scans and emphysema, micronodules and bronchial wall thickening on inspiratory scans. The ratio of expiratory and inspiratory mean lung attenuation (E/I) was calculated as a measure of static (fixed) air trapping. Regional air trapping was present in 63% of current smokers, in 45% of never smokers and in 8% of COPD patients (p&lt;0.001). Current smokers with and without regional air trapping had E/I ratio of 0.81 and 0.91, respectively (p&lt;0.001). Forced expiratory volume in 1 s (FEV 1 ) was significantly higher and emphysema less frequent in current smokers with regional air trapping. Current smokers with regional air trapping had higher FEV 1 and less emphysema on computed tomography. In contrast, current smokers without regional air trapping resembled COPD. Our results highlight heterogeneity among smokers with normal spirometry and may contribute to early detection of smoking related structural changes in the lungs.
Role of the IL28B Rs12979860 C/T Polymorphism on the Incidence of Clinically-Active Cytomegalovirus Infection in Autologous Stem Cell Transplant Patients
Authors: Ombretta Annibali, Elisabetta Riva, Livia Piccioni, Francesca Chiodi, Valeria Tomarchio, Daniele Armiento, Erika Circhetta, Alessandra Scardocci, Silvia Ferraro, Maria Cristina Tirindelli, Giuseppe Avvisati
Journal: Blood (2015)
Front-line high-dose chemotherapy (HDT) combined with rituximab for adults with aggressive large B cell lymphoma (DLBCL). A pilot study by the GOELAMS
Authors: N. J. Milpied, T. Lamy, P. Casassus, E. Deconninck, R. Gressin, C. Le Maignan, O. Tournilhac, J. Dugay, E. Legouffe, V. Delwail
Journal: Journal of Clinical Oncology (2004)

6662 Background: The beneficial effect of adding rituximab to CHOP has been shown for elderly patients with DLBCL (Coiffier et al NEJM 2002). We have shown that HDT with autologous stem cell transplantation is superior to CHOP in young adults with DLCL (Milpied et al NEJM in press). The feasibility of adding rituximab to front-line HDT remains to be established. Methods: A prospective pilot trial was proposed to patients with DLBCL, with intermediate-high or high age-adjusted IPI, up to the age of 60 y.o. This program consisted of 2 courses of high-dose CHOP-like regimen, 15 days apart, with rituximab (375 mg/ m2) on d1 of each course, followed by rituximab on d 22, harvest of peripheral blood stem cells (G-CSF mobilized) on days 28,29, then rituximab on d 36 followed by a course of high-dose methotrexate with cytarabine and by a BEAM regimen starting on d 66 to 80, followed by the infusion of stem cells. Results: Between 04/2002 and 05/2003, 41 consecutive patients gave their informed consent and were included in that trial. Their median age was 50y.o.( 18–60 yo); 23 had WHO PS >/= 2, the LDH level was > N in 37 patients and 38 had Ann Arbor stage III or IV. The age-adjusted IPI was intermediate-high in 21 and high in 19 patients.At the time of this abstract, the program has been completed in 75% of the patients. Three patients died of toxicity of the treatment before the BEAM regimen and autologous transplantation. On an intent-to-treat basis, the response rate at the end of the treatment was CR/CRu= 64%, PR=8%, failure to achieve a response or progression= 20% and toxic death=8%. No toxic death was directly attributable to the addition of rituximab. Conclusions: The addition of 4 doses of rituximab to this HDT program is feasible with no unexpected toxicity, allows the harvesting of sufficient numbers of stem cells to allow an autologous transplantation following a BEAM regimen in responding patients . Follow-up and comparison with historical control will be performed and presented Author Disclosure Employment or Leadership Consultant or Advisory Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Roche Pharmaceutical Roche France
Nonmyeloablative Allogeneic Stem Cell Transplantation (NST) for Hematologic Malignancies (HM) Using Pentostatin/Low-Dose Total Body Irradiation (TBI).
Authors: R. Gregory Bociek, James E. Talmadge, James C. Lynch, Charles A. Enke, Charles A. Kuszynski, Philip J. Bierman, Julie M. Vose, James O. Armitage, Marcel P. Devetten, Lori J. Maness, Timothy R. McGuire, James L. Wisecarver, Shantaram S. Joshi, Zivko S. Pavletic
Journal: Blood (2005)
Containing Zika while we wait for a vaccine
Authors: Ranu S Dhillon, Devabhaktuni Srikrishna, Ashish K Jha
Journal: BMJ (2017)

Though no longer considered an emergency by the World Health Organization, Zika virus has reached over 70 countries and continues to spread. 1 As long as each infected person infects, on average, at least one other person, the pandemic will grow.In highly affected areas, widespread infection and herd immunity could ultimately stall transmission but only after devastating consequences for new babies. 24][5][6][7] In the interim, measures to eliminate mosquitoes, such as aerial spraying, cannot be effectively applied across over 70 countries.Other approaches are needed to stem transmission.Eliminating mosquitoes is absolutely necessary only if there is substantial vertical transmission from mosquitoes to their offspring.For Zika, this is rare (1 in 290) 8 and insignificant compared with human mediated spread through mosquitoes and sex.About 80% of infected people are asymptomatic and therefore unaware they are propagating transmission.This "invisible" spread makes it difficult to know Zika's true transmission rate-estimates range from 1.4 to 6.6 new infections per infected person. 9Recently, the US government announced a $20m (£16m; €19m) competition for point-of-care tests for antimicrobial resistance.A similar initiative is needed for Zika.
Upregulation of Indoleamine 2,3-Dioxygenase Enzymes in Leukemic Mesenchymal Stromal Cells (MSCs) Can Influence MSC/Acute Myeloid Leukemia Cell Cross Talk
Authors: Marilena Ciciarello, Giulia Corradi, Carmen Baldazzi, Nicoletta Testoni, Roberto Massimo Lemoli, Michele Cavo, Antonio Curti
Journal: Blood (2015)
Waldenström macroglobulinemia: 2017 update on diagnosis, risk stratification, and management
Authors: Morie A. Gertz
Journal: American Journal of Hematology (2017)

Disease Overview: Waldenström macroglobulinemia (WM) is a lymphoplasmacytic lymphoma with immunoglobulin M (IgM) monoclonal protein. Clinical features include anemia, thrombocytopenia, hepatosplenomegaly, lymphadenopathy, and rarely hyperviscosity. Diagnosis: Presence of IgM monoclonal protein associated with ≥10% clonal lymphoplasmacytic cells in bone marrow confirms the diagnosis. The L265P mutation in MYD88 is detectable in more than 90% of patients. Risk Stratification: Age, hemoglobin level, platelet count, β 2 microglobulin, and monoclonal IgM concentrations are characteristics required for prognosis. Risk‐Adapted Therapy: Not all patients who fulfill WM criteria require therapy; these patients can be observed until symptoms develop. Rituximab‐based therapy is used in virtually all U.S. patients with WM and can be combined with bendamustine, an alkylating agent, or a proteosome inhibitor. Purine nucleoside analogues are widely used in Europe. The preferred Mayo Clinic nonstudy therapeutic induction is rituximab and bendamustine. Potential for stem cell transplantation should be considered in induction therapy selection. Management of Refractory Disease: Bortezomib, fludarabine, thalidomide, everolimus, ibrutinib, carfilzomib, lenalidomide, and bendamustine have all been shown to have activity in WM. Given WM's natural history, reduction of complications will be a priority for future treatment trials. Am. J. Hematol. 92:209–217, 2017. © 2016 Wiley Periodicals, Inc.
A trade deal between the United Kingdom and United States
Authors: Martin McKee, Pepita Barlow, David Stuckler
Journal: BMJ (2017)

Be careful what you wish for

The UK has something to celebrate, at least if you believe the tabloid headlines. It seems that it has moved from the back to the front of the queue to agree a trade deal with the US.

On the surface, a trade deal would be a good idea. The UK must now prepare to negotiate such deals with many countries, to replace those from which it will be excluded when it leaves the European Union.1 Failure to agree them risks defaulting to World Trade Organisation regulations, which would be severely damaging. Tariffs would make many British goods more expensive, and it may be impossible to trade some of the services that are now a major source of the UK’s foreign earnings. More important are non-tariff barriers, such as regulations and standards that allow the European single market to work, even if often mocked by Eurosceptics. Worst of all are quotas, which limit the amount of goods that overseas markets will import.

Although, in theory, the UK is entitled to a share of the EU’s quotas for international trade, in practice, negotiating this is fiendishly difficult. A recent worked example using something as seemingly simple as lamb and mutton quotas showed that this could take years to …
The Role of Cranial Irradiation (CRT) or Extended Triple Intrathecal Therapy (T.I.T.) in Childhood T-Cell ALL; the ALL Israel National Studies (INS) 89 and 98 (Modified ALL-BFM 86 and 95) Report.
Authors: Batia Stark, Dina Attias, Gali Avrahami, Ami Ballin, Bela Bielorai, Yoav Burstein, Ronit Elhasid, Herzel Gavriel, Josef Kapelushnik, Hagit Miskin, Dalia Sthoeger, Michael Weintraub, David Steinberg, Shai Izraeli
Journal: Blood (2006)
Optimizing Outcomes in Multiple Myeloma Using Risk Stratified Allocation to Single Versus Tandem Autologous SCT.
Authors: Matthew Risendal, Roy T Sabo, Allison F Hazlett, Priscilla Mpasi, Joan Bolling, William B Clark, John M McCarty, Harold M Chung, Catherine H Roberts, Amir A Toor
Journal: Blood (2012)
Thalidomide and Dexamethasone Is an Effective Salvage Regimen for Myeloma Patients Relapsing after Autologous Transplant.
Authors: Antonio Palumbo, Patrizia Falco, Maria Teresa Ambrosini, Tommaso Caravita, Pellegrino Musto, Maria Teresa Petrucci, Patrizia Pregno, Ilaria Avonto, Alessandra Bertola, Sara Bringhen, Federica Cavallo, Giovannino Ciccone, Mario Boccadoro
Journal: Blood (2004)
Murine NK Cells Require Activation-Dependent Expression of Granzyme B and Perforin To Become Potent Cytotoxic Effectors.
Authors: Todd A. Fehniger, Sheng F. Cai, Xuefang Cao, Andrew J. Bredemeyer, Rachel M. Presti, Anthony R. French, Timothy James Ley
Journal: Blood (2006)
Telomere Dynamics in Monoclonal B-Cell Lymphocytosis and Binet a Chronic Lymphocytic Leukemia
Authors: Felipe M Furtado, Daniel M Matos, Natalia Ferreira Scatena, Barbara Santana, Priscila Santos Sheucher, Eduardo Magalhaes Rego, Rodrigo T. Calado, Roberto P. Falcao
Journal: Blood (2015)
Quantification of whole-blood EBV DNA in immunocompetent patients with lymphoma.
Authors: B. E. Beltran, J. J. Castillo, C. R. Desposorio, F. Hurtado de Mendoza, E. M. Sotomayor
Journal: Journal of Clinical Oncology (2011)

e18524 Background: Epstein-Barr virus (EBV) is an oncovirus associated with several lymphomas. Quantification of EBV viral loads has been reported as a potential biomarker for EBV+ lymphoma. The goal of our study was to detect whole blood EBV DNA viral load at lymphoma diagnosis and correlate it with expression of EBV-encoded RNA (EBER) in tumor tissue. Methods: Between January to December 2009, 59 immunocompetent patients with a diagnosis of lymphoma were included. Five cc of whole blood were taken at diagnosis to determine EBV viral loads using real-time quantitative PCR. EBV in the tumor cells was evaluated by detecting EBER using a chromogenic in situ hybridization (ISH) technique. Results: From 59 patients, 46 (78%) had diffuse large B-cell lymphoma (DLBCL), 3 (5%) Hodgkin, 3 (5%) NK/T-cell extranodal (NKTCL), 4 (7%) adult T-cell leukemia/lymphoma (ATLL), 1 (2%) peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS), 1 (2%) subcutaneous T-cell panniculitis-like lymphoma (SQPL) and 1 (2%) Hydroa-vacciniforme-like lymphoma (HVLL). Twelve cases (20%) showed elevated levels of EBV DNA ranging between 0.25-46,400 copies/ul. Six (50%) were DLBCL, 2 (17%) were NKTCL, 2 (17%) were ATLL, 1 (8%) Hodgkin and 1 (8%) HVLL. Ten cases (83%) expressed EBER in tumor tissue. Eight (80%) were EBER+ within tumor cells and 2 (20%) were positive within the microenvironment. Five (out of 6, 83%) DLBCL cases were positive for EBER. These cases were later defined as EBV+ DLBCL of the elderly (WHO). Two ATLL cases were EBER+ in the microenvironment. Two (out of 3, 66%) NKTL patients had detectable levels of EBV DNA as well as our case of HVLL; these 3 cases were positive for EBER. Conclusions: These results suggest that whole blood EBV DNA quantification correlates with the expression of EBER, detected by ISH, within the tumor tissue and might be of value as a biomarker in patients with EBV+ lymphomas, especially EBV+ DLBCL of the elderly. ATLL expresses EBER within the tumor microenvironment.
Bone Marrow Stromal Cells Modulate Sensitivity of CXCR4-Deficient CML Cells to Pharmacological Inhibitors of PI3K/AKT Signaling.
Authors: Linhua Jin, Yoko Tabe, Nobuko Tanaka, Yuanyuan Xu, Atsushi Kato, Hagop Kantarjian, Michael Andreeff, Marina Konopleva
Journal: Blood (2005)
Assessment of the Potential of Immature CD19+CD21- B-Lymphocytes to Predict Response to Various Systemic Therapies in Chronic Graft-Versus-Host Disease.
Authors: Zoya Kuzmina, Hildegard Greinix, Roman Weigl, Sandra Eder, Robert Knobler, Ulrike Koermoeczi, Arno Rottal, Christoph C Zielinski, Winfried F. Pickl
Journal: Blood (2009)
Combination Therapy with Novel Nanoparticle, SNS01-T, and Lenalidomide Triggers Synergistic Cytotoxicity in Vitro and in Vivo in Multiple Myeloma and Mantle Cell Lymphoma
Authors: Catherine A Taylor, Terence Tang, Zhongda Liu, Sarah Francis, Zheng Qifa, Richard Dondero, John Thompson
Journal: Blood (2012)
High Resolution Array-Based Analysis in Marginal Zone Lymphomas and Lymphoplasmacytic Lymphomas Identified Disease-Specific Patterns of Chromosome Abnormalities
Authors: Esteban Braggio, Ellen Remstein, Wee Joo J Chng, Gaofeng Huang, Michael Barrett, Thomas E. Witzig, Ahmet Dogan, Rafael Fonseca
Journal: Blood (2008)
Acceptable Outcomes for Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation (AlloSCT) for Relapsed Aggressive Non-Hodgkin’s Lymphoma (NHL).
Authors: Richard T. Doocey, Kevin W. Song, Cynthia L. Toze, Joseph M. Connors, Thomas J. Nevill, Randy D. Gascoyne, Michael J. Barnett, Donna L. Forrest, Donna E. Hogge, Julye C. Lavoie, Stephen H. Nantel, John D. Shepherd, Heather J. Sutherland, Nicholas Voss, Clayton A. Smith
Journal: Blood (2004)
Update: A 43-Year-Old Man With Angina, Elevated Troponin, and Lateral ST Depression
Authors: Neha S. Trivedi, Amy N. Ship, Duane S. Pinto
Journal: JAMA (2011)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal